Oncoinvent would like to extend an invitation to a presentation of the Q3 2021 results. The presentation will be held virtually via Teams at 09:00 on Friday 12. November 2021. We request that participants register with email@example.com for logon details.
Twenty-three colorectal cancer patients in total have been enrolled in the Radspherin® RAD-18-002 phase 1 clinical trial and treated with Radspherin®. No SAE’s related to the Radspherin® treatment have been observed.
Oncoinvent to present four posters at the 34th Annual Congress of the European Association of Nuclear Medicine
Oncoinvent presents preclinical dosimetry data documenting a therapeutic relevant biodistribution of Radspherin® as well as preclinical data on the potential synergistic effects of Radspherin® with existing cancer therapies. The company also will present preclinical results of a novel 212Pb product candidate
The company makes three important new appointments to the clinical and regulatory teams in preparation for the upcoming Radspherin® phase 2 clinical trials
Safety Monitoring Committee review of third dose-level cohort allows progression of Phase 1 RAD-18-001 study to fourth and final cohort dose level cohort
Oncoinvent would like to extend an invitation to a presentation of the Q2 2021 results. The presentation will be held virtually via Teams at 09:00 on Thursday 9. September 2021. We request that participants register with firstname.lastname@example.org for logon details.
Norwegian radiopharmaceutical company announces successful closing of a private placement that will allow the company to initiate the next phase of clinical development of its lead product candidate Radspherin®
Norwegian radiopharmaceutical company is contemplating a private placement to raise funds for the phase 2A development of it’s lead product candidate Radspherin®